Bio-Rad Laboratories Inc. (BIO) Stock

Valuation data is not available for this stock.

With a beta of 0.94, Bio-Rad Laboratories Inc. is less volatile than the overall market. This means when the market moves up or down by 10%, this stock typically moves less than 10% in the same direction. Lower beta stocks are often preferred by conservative investors seeking stability. The price-to-book ratio of 0.99 indicates the stock trades below its accounting value, which could signal value or distress.

Bio-Rad Laboratories Inc. achieves a profit margin of -85.20%, meaning it retains $-85.20 from every $100 in revenue after all expenses. This relatively low margin suggests the company operates in a competitive environment or high-cost industry where profitability is challenging. The operating margin of 9.72% reveals how efficiently the company runs its core business operations before interest and taxes. With ROE at -27.50% and ROA at 1.55%, the company achieves moderate returns on invested capital.

Bio-Rad Laboratories Inc.'s revenue declined by 4.20% year-over-year, indicating challenges in maintaining sales momentum. This contraction may reflect market headwinds, competitive pressures, or strategic transitions. Earnings decreased by 83.00% year-over-year, reflecting the bottom-line impact of business performance. These growth metrics should be evaluated against LABORATORY ANALYTICAL INSTRUMENTS industry averages for proper context.

Bio-Rad Laboratories Inc. has a market capitalization of $6.59B, classifying it as a mid-cap stock ($2B-$10B). Mid-caps often represent companies in their growth phase, offering higher growth potential than large-caps but with more stability than small-caps. They can be attractive takeover targets and may become tomorrow's large-caps. With 22.14M shares outstanding, the company's ownership is relatively concentrated. As a participant in the LABORATORY ANALYTICAL INSTRUMENTS industry, it competes with other firms in this sector.

Bio-Rad Laboratories Inc.'s book value per share is $241.72, while the current stock price is $246.53, resulting in a price-to-book (P/B) ratio of 1.02. This reasonable premium to book value suggests the market values the company's earnings power and intangible assets appropriately. Most profitable companies trade between 1-3x book value. As a common stock, this represents equity ownership with voting rights.

6 analysts cover BIO with 67% recommending buy/strong buy ratings. Analyst predictions have mixed reliability - studies show consensus rarely beats market returns consistently. The mixed views reflect uncertainty about the outlook. The consensus target of $315.33 implies 27.9% upside, but targets are often adjusted to follow price moves rather than predict them.

Current analyst recommendations:2 Strong Buy, 2 Buy, 2 Hold, 00The bullish tilt suggests optimism about future prospects, though investors should conduct independent research.Remember that analyst opinions often lag price movements and can be influenced by investment banking relationships.

RSI data is not available for this stock.

MACD and moving average data are not available for this stock.